Trans-spinal magnetic stimulation
DeviceTrans-spinal magnetic stimulation activates afferent spinal roots and increases cortical excitability.
Other names: tsMS, transcutaneous spinal cord magnetic stimulation
NCT Number: NCT06593184
The goal of this clinical trial is to learn if trans-spinal magnetic stimulation works to treat gait disorders in chronic stroke adults. It will also learn about the safety of trans-spinal magnetic stimulation.
The main questions it aims to answer are:
Does trans-spinal magnetic stimulation enhance chronic stroke participants gait and functional mobility? Does the technique cause any side effects?
Researchers will compare trans-spinal magnetic stimulation to a sham (a look-alike stimulation with no real effect) to see if trans-spinal magnetic stimulation works to treat gait disorders and improve functional mobility.
Participants will:
Receive trans-spinal magnetic stimulation with treadmill training or a sham stimulation with treadmill training every day for 2 weeks.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Federal University of Paraiba, João Pessoa, Paraíba, Brazil
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Trans-spinal magnetic stimulation activates afferent spinal roots and increases cortical excitability.
Other names: tsMS, transcutaneous spinal cord magnetic stimulation
Sham trans-spinal magnetic stimulation involves masking, where the sound of stimulation persists even though no magnetic pulses are delivered
Time frame: Enrollment (Day 0); End of treatment (2 weeks); Follow-up after 30 days post-treatment
The Timed-Up and Go (TUG) test is used to evaluate an individual´s capacity to stand up, walk, and sit down. During the test, the participants are timed from the moment they begin to stand up until they are seated again.
Time frame: Enrollment (Day 0); End of treatment (2 weeks); Follow-up after 30 days post-treatment
Self-reported independence is assessed using the Functional Ambulation Categories (FAC). Scores range from 0 (inability to walk even with external help) to 5 (normal ambulation).
Time frame: Enrollment (Day 0); End of treatment (2 weeks); Follow-up after 30 days post-treatment
Motor function of the lower limbs is assessed using the Fugl-Meyer Assessment, where scores range from 0 (indicating the worst motor function) to 28 (indicating normal motor function).
Time frame: Enrollment (Day 0); End of treatment (2 weeks); Follow-up after 30 days post-treatment
Capacity to maintain balance during various tasks is assessed using the Mini Balance Evaluation System (MiniBEST-test). Its scores range from 0 to 28 points. Lower scores indicate poor balance, while higher scores reflect better balance.
Time frame: End of treatment (2 weeks)
Evaluation of how the participant describes the perceived change in their condition since the treatment started, using the Patient Global Impression of Change (PGM). This scale assesses the change in activity limitations, symptoms, emotions, and overall quality of life since the beginning of treatment, ranging from no change or worsening to significant improvement that made a considerable difference. A score of one indicates no change, while a score of seven represents a substantial improvement.
Time frame: Enrollment (Day 0); End of treatment (2 weeks); Follow-up after 30 days post-treatment
Tonus disorders will be assessed using the Modified Ashworth Scale, which measures spasticity by grading muscle resistance during passive stretching. The scale ranges from 0 to 4, where 0 indicates no increase in muscle tone, and 4 represents a limb that is rigid in flexion or extension.
Time frame: Enrollment (Day 0); End of treatment (2 weeks); Follow-up after 30 days post-treatment
Assessed using a method inspired by the ASIA scale, evaluating the lower thoracic, mid-thoracic, and lower cervical dermatomes, where a score of 0 indicates absence of sensitivity and 2 indicates normal sensitivity.
Contact information is provided by the study sponsor or research team.
Universidade Federal de Pernambuco
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07113067
Abulia, Apathy
Charleston, South Carolina, United States
View Trial DetailsNCT04188522
Brain Diseases, Cardiovascular Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT05626894
Brain Diseases, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06797154
Brain Diseases, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial Details